Add Dr Lal Pathlabs, goal worth Rs 2,910: HDFC Securities

HDFC Securities has an add name on Dr Lal Pathlabs with a goal worth of Rs 2910. The present market worth of Dr Lal Pathlabs is Rs 2566. Dr Lal Pathlabs., included in 1995, is a Mid Cap firm with a market cap of Rs 21380.49 crore, working in Hospitals & Allied Providers sector.

Dr. Lal Pathlabs’ key merchandise/income segments embody Hospital Providers and Different Working Income for the yr ending 31-Mar-2022.

Financials For the quarter ended 31-12-2024, the corporate has reported a Consolidated Complete Revenue of Rs 621.80 crore, down -8.84 % from final quarter Complete Revenue of Rs 682.10 Crore and up 11.59 % from final yr similar quarter Complete Revenue of Rs 557.20 crore. The corporate has reported internet revenue after tax of Rs 98.10 Crore in newest quarter.

The corporate?s high administration consists of Brig.(Hony) Dr.Arvind Lal, Mr.Rohit Bhasin, Mrs.Somya Satsangi, Mr.Rajit Mehta, Mr.Gurinder Singh Kalra, Dr.Archana Lal Erdmann, Mr.Rahul Sharma, Dr.Vandana Lal, Dr.Om Prakash Manchanda, Mr.Arun Duggal. Firm has Deloitte Haskins & Sells LLP as its auditors. As on 31-12-2024, the corporate has a complete of 8 Crore shares excellent.

Funding RationaleThe diagnostic sector skilled de-rating in the previous few quarters because of reasonable earnings development, and DLPL is buying and selling at 42x/37x PE; that is at an 15/24% low cost to its long-term imply of 49x. HDFC Securities has tweaked its estimates and rolled ahead the goal worth to Rs 2,910, based mostly on a 43x FY27E EPS (~10% low cost to the typical PE of 49x), which suggests 26x EV/EBITDA. Whereas the brokerage has inbuilt 5% sufferers and 10% samples quantity CAGR for FY25-27E, they are going to preserve monitor of the development in quantity and earnings development. HDFC Securities maintains an ADD score. Promoter/FII Holdings Promoters held 53.91 per cent stake within the firm as of 31-Dec-2024, whereas FIIs owned 26.82 per cent, DIIs 12.87 per cent.